Cannabics Pharmaceuticals Inc. Files Patent Application Which Covers Novel Personalized Anti-Cancer Treatment
PR Newswire - Thu May 28, 7:10AM CDT
Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive patent application with the US Patent & Trademark Office (USPTO) on a System and Method for High Throughput Screening of Cancer Cells.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part III
Anthony Cataldo - at Seeking Alpha - Thu Apr 16, 12:51PM CDT
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST
INSY: 37.53 (+0.49), FULL: 3.56 (+0.05), CARA: 13.28 (+0.52)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 125.86 (+5.39), FULL: 3.56 (+0.05), CARA: 13.28 (+0.52)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 125.86 (+5.39), FULL: 3.56 (+0.05), CARA: 13.28 (+0.52), ICN: 21.43 (-0.05)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 125.86 (+5.39), FULL: 3.56 (+0.05), CARA: 13.28 (+0.52)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 125.86 (+5.39), DE: 95.17 (+0.63), FULL: 3.56 (+0.05), CARA: 13.28 (+0.52)
Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 125.86 (+5.39), FULL: 3.56 (+0.05)
Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain
Marketwired - Thu Nov 06, 7:32AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.
Cannabics Pharmaceuticals, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Mon Oct 27, 7:01PM CDT
Bethesda, MD / ACCESSWIRE / October 27, 2014 / Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) will be presenting at the Cannabis Investor Webcast on Tuesday, October 28, 2014 at 11:00 AM ET.
Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel
Marketwired - Mon Oct 20, 8:05AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.